ArticleFrontiers in oncology2026
Proteomic analysis of saliva reveals changes in proteomic profiles during colorectal cancer in an Iranian cohort.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Colorectal cancer (CRC) is common and associated with poor survival, and early detection is pivotal to improving patient outcomes. Therefore, identifying reliable biomarkers reflecting early-stage tumor development is of major clinical importance. This study aimed to identify salivary proteins with potential as non-invasive biomarkers associated with early-stage CRC. Methods: A total of 104 saliva samples were collected from individuals undergoing CRC screening, including patients diagnosed with CRC stage I and non-cancer controls (NCC), at Taleghani Hospital, Tehran, Iran, in this case-control study. A quantitative label-free proteomics approach was applied to determine global proteome differences between CRC patients and NCCs and to identify proteins with altered abundance. Proteins were extracted from saliva samples, digested with trypsin, and peptides were analyzed using LC-MS/MS on an Orbitrap Fusion mass spectrometer. Results: A total of 2,456 salivary proteins were identified, of which 181 showed significantly different abundance between CRC patients and NCCs. Unsupervised clustering demonstrated partial separation of groups with influence from demographic variables. Members of the small proline-rich protein (SPRR) family emerged as consistent core markers distinguishing CRC from NCCs, while additional immune- and metabolism-associated proteins contributed to group differentiation. Demographic subgroup analyses, including age-, sex-, and smoking-stratified comparisons, revealed subgroup-associated differences in protein abundance patterns; however, several CRC-associated alterations remained detectable across subgroups, including middle-aged individuals. Gene set enrichment analysis indicated suppression of cytoskeletal and epithelial structural pathways alongside enrichment of protease regulatory pathways. Ingenuity Pathway Analysis identified an interconnected immune-metabolic network characterized by inflammatory signaling and oxidative stress-related processes. These alterations indicate immune-related and metabolic signaling changes associated with CRC. Discussion: This study supports salivary proteomics as a non-invasive approach for early CRC detection, and the observed proteomic signatures may reflect systemic tumor-immune interactions associated with CRC. Data are available via ProteomeXchange with identifier PXD078610.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.